BCM
KROS icon

Bridgeway Capital Management’s Keros Therapeutics KROS Stock Holding History

Bridgeway Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.84M Buy
265,017
+70,000
+36% +$780K 0.05% 464
2026
Q1 		$2.15M Buy
195,017
+134,939
+225% +$2.08M 0.04% 511
2025
Q4 		$1.22M Buy
+60,078
New +$1.05M 0.03% 665

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Bridgeway Capital Management's KROS Position: Q2 2026 in Review

Bridgeway Capital Management increased its Keros Therapeutics (KROS) stake by 36% in Q2 2026, buying an estimated $780K and bringing the position to 265,017 shares worth $2.84M. The position accounts for 0.05% of the portfolio, ranked #464.

Bridgeway Capital Management first reported a position in KROS in Q4 2025 and has held it in 3 quarters since. 133 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Bridgeway Capital Management held 265,017 shares of Keros Therapeutics worth $2.84M as of Q2 2026.
  • Bridgeway Capital Management bought 70,000 Keros Therapeutics shares in Q2 2026, an estimated $780K.
  • Keros Therapeutics made up 0.05% of Bridgeway Capital Management's portfolio in Q2 2026, its #464 holding.
  • Bridgeway Capital Management first reported a position in Keros Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 133 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.